Ira Spector
Algemeen Directeur bij SFA Therapeutics, Inc.
Actieve functies van Ira Spector
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
SFA Therapeutics, Inc.
 SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Algemeen Directeur | 01-08-2017 | - |
Loopbaan van Ira Spector
Eerdere bekende functies van Ira Spector
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ICON PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 10-09-2014 | - |
Opleiding van Ira Spector
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
| Drexel University | Masters Business Admin |
| Washington University in St. Louis | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
| Ierland | 2 |
Operationeel
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Consumer Services | 4 |
| Commercial Services | 2 |
| Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ICON PUBLIC LIMITED COMPANY | Commercial Services |
| Bedrijven in privébezit | 1 |
|---|---|
SFA Therapeutics, Inc.
SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Technology Services |
- Beurs
- Insiders
- Ira Spector
- Ervaring
